Document:

Exhibit

EXHIBIT 10.9

Amendment No. 2 to the Pfizer Supplemental Savings Plan 
(the “PSSP”)

*     *     *

(New material underlined twice; deletions crossed out)

		
	1.
	New Sections are added as additional definitions in Article II to read as follows and the Sections in Article II shall be renumbered as appropriate:

Pension Transfer. The term “Pension Transfer” shall mean a Member who is actively employed and eligible to accrue a defined benefit under the Pfizer Consolidated Pension Plan on December 31, 2017, and who becomes a Retirement Savings Eligible Employee on January 1, 2018.
TCN Transfer. The term “TCN Transfer” shall mean an amount transferred into the Plan of the balance of an individual’s benefits under the Pfizer Inc. Third Country National Plan and credited under the Plan. Distribution of a TCN Transfer from the Plan will begin the January following the Member’s Separation from Service in a lump sum payment. A TCN Transfer may be re-deferred as provided in Section 6.8.
		
	2.
	Section 2.31 is amended to add the following language to the end thereof to read as follows:

2.31    Regular Earnings.
...
However, for Pension Transfers, solely for purposes of the Retirement Savings Contribution, Regular Earnings shall not include any GPP bonus paid or deferred in 2018 which reflects payment for services performed in 2017.

		
	3.
	Section 3.5 is amended to add new subsection (c) to read as follows:

(c) For any Pension Transfer, the definition of “Regular Earnings” in connection solely with the calculation of the 2018 Retirement Savings Contributions under the Plan for such Pension Transfer shall not include any GPP bonus paid to or deferred by such Pension Transfer during 2018 which reflects performance during 2017. 

		
	4.
	The first sentence of Section 5.1 is amended to read as follows:

5.1    Creation of Accounts. The Company will maintain an Account (which may include Special Accruals) under the Plan in the name of each Member, as well as separate Accounts for a Member’s Active Death Benefit SERP Transfer, Transfer to PSPP, In Service Transfer to PSSP, and TCN Transfer, if applicable. 

		
	5.
	New Appendix E is added to read as follows:

APPENDIX E
SPECIAL PROVISIONS APPLICABLE TO LEGACY WYETH, WARNER LAMBERT, AND PHARMACIA EMPLOYEES

Effective as of January 1, 2018, each of the legacy Wyeth employees (“Wyeth Employees”), legacy Warner-Lambert Inc. employees (“WL Employees”), and legacy Pharmacia Corp. employees (“Pharmacia Employees”) who are PRAP Members, shall become eligible to participate in the Retirement Savings Contribution under the Plan in connection with the freeze of the pension plans. In connection with the calculation of the Retirement Savings Contribution, the provisions shall follow the applicable provisions of the Qualified Plan.

		
	6.
	New Appendix F is added to read as follows:

APPENDIX F
SPECIAL PROVISIONS APPLICABLE TO ANACOR PHARMACEUTICALS, INC., HOSPIRA, INC., AND MEDIVATION, INC. EMPLOYEES

Effective as of the respective effective dates listed below, each of the legacy Anacor Pharmaceuticals, Inc. employees (“Anacor Employees”), the legacy Hospira, Inc. employees (“Hospira Employees”), and legacy Medivation, Inc. employees (“Medivation Employees”), shall be eligible to participate in the Plan. Years of Service shall be credited as provided under the Qualified Plan. “Regular Earnings” shall include only compensation on and after the date the participant becomes eligible under the Plan, and shall not include any GPP bonus paid or deferred with respect to services performed before eligibility in the Plan for purposes of the calculation of the Retirement Savings Contribution. In addition, for Hospira Employees, Regular Earnings shall not include any GPP bonus paid or deferred with respect to services performed before eligibility in the Plan for purposes of Contributions under the Plan. 

		
	1.
	Anacor Employees shall be eligible to participate in the Plan on and after September 1, 2017. 

		
	2.
	Hospira Employees shall be eligible to participate in the Plan on and after January 1, 2018.  

		
	3.
	Medivation Employees shall be eligible to participate in the Plan on and after January 1, 2018.Exhibit

EXHIBIT 10.26

Form of Special Performance-Based Incentive Award Letter

Pfizer Inc
235 East 42nd Street 
New York, NY 10017-5755

        
[DATE]
[NAME]
[ADDRESS]

Dear [NAME]

The purpose of this letter is confirm that on [DATE], the Compensation Committee of the Board of Directors of Pfizer Inc. approved the following grant for you under Pfizer’s Executive Long-Term Incentive Program (“Program”).
	
				
	

Award Type
	Grant Price
	

Shares (#)
	

Dates

	5-Year Performance Total Shareholder Return Units (“5-YR PTSRUs”) 

	[$XX.XX]
	[###]

	Grant Date [DATE]
Vesting Date – (See Below )
Settlement Date [DATE]

The 5-Yr PTSRUs are subject to the following performance requirements: (i) your continuous employment by Pfizer through [Date] (or such earlier time as determined by the Board) and you are either employed by Pfizer or are subject to and comply with a non-compete and non-solicitation agreement until [DATE]; and (ii) Pfizer’s total shareholder return (TSR) is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on the fifth anniversary of the grant date, [DATE]).

The TSR performance condition will not be waived for any reason including: death, termination without cause or disability. The service condition will be waived and the award will only vest and settle upon your death immediately following the performance condition being achieved either before death or within the five-year term. Upon termination without cause or long-term disability, the service condition will be waived (excluding the non-compete or non-solicitation provisions) and, if the performance condition is met, the award will vest and settle on the fifth anniversary of grant. The PTSRUs will be forfeited if the TSR goal (at least 25% or higher on average for 30 consecutive trading days) is not attained during the performance period.

Your award is contingent upon your acceptance by [DATE] of the terms and conditions in the Grant Agreement, including the restrictive covenants/non-compete provisions, which will be sent to you in the near future. Additional information about your grant is included in the generic Executive Points of Interest (POI) document and Pfizer Inc. 2014 Stock Plan which are posted on Fidelity NetBenefits.  The Grant Agreement and POI document provide you with more detailed information about your grant and contain general information about the Program, applicable income tax consequences, and points of contact.  This long-term incentive grant is governed by the terms and conditions set forth in this letter and the Grant Agreement, POI document and Pfizer Inc. 2014 Stock Plan.  

It is important for you to read these materials, and sign and return the Grant Agreement to [NAME] by [DATE].  It is recommended that you consult a qualified financial or tax advisor before making any decisions regarding the disposition of the stock resulting from the vesting of these awards.   

This award is in recognition of what you have done and will continue to do for Pfizer and its patients, employees and shareholders.   I have great confidence in Pfizer’s future, and I look forward to working with you toward that future.  

Sincerely,
[SIGNATURE]Exhibit

EXHIBIT 10.27
Form of Special Performance-Based Incentive Grant Letter

                

Pfizer Inc
235 East 42nd Street 
New York, NY 10017-5755

        
[DATE]
[NAME]
[ADDRESS]

Dear [NAME]:

I am pleased to confirm to you that on [DATE], the Compensation Committee of the Board of Directors of Pfizer Inc. approved the following grant for you under Pfizer’s Executive Long-Term Incentive Program (“Program”).
	
				
	

Award Type
	Grant Price
	

Shares (#)
	

Dates

	5-Year Performance Total Shareholder Return Units (“5-YR PTSRUs”) 

	[$XX.XX]
	[###]

	Grant Date – [DATE]
Vesting Date – See Below 
Settlement Date – [DATE]

	Restricted Stock Units (“RSUs”) 

	[$XX.XX]
	[###]
	Grant Date – [DATE]
Vesting Date – [DATE]

The PTSRUs are subject to the following performance requirements: (i) your continuous employment by Pfizer through [DATE]; and (ii) Pfizer’s total shareholder return (TSR) is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on the fifth anniversary of the grant date, [DATE]).

The TSR performance condition will not be waived for any reason including: death, termination without cause or disability. The service condition will be waived and the award will vest and settle upon your death immediately following the performance condition being achieved either before death or within the five-year term. Upon termination without cause or long-term disability, the service condition will be waived and, if the performance condition is met, the award will vest and settle on the fifth anniversary of grant. The PTSRUs will be forfeited if the TSR goal (at least 25% or higher on average for 30 consecutive trading days) is not attained during the performance period.

Your award is contingent upon your acceptance by [DATE]of the terms and conditions in the Grant Agreement, including the restrictive covenants/non-compete provisions, which will be sent to you in the near future. Additional information about your grant is included in the generic Executive Points of Interest (POI) document and Pfizer Inc. 2014 Stock Plan which are posted on Fidelity NetBenefits.  The Grant Agreement and POI document provide you with more detailed information about your grant and contain general information about the Program, applicable income tax consequences, and points of contact.  This long-term incentive grant is governed by the terms and conditions set forth in this letter and the Grant Agreement, POI document and Pfizer Inc. 2014 Stock Plan. 

It is important for you to read these materials, and sign and return the Grant Agreement to [NAME] by [DATE].  It is recommended that you consult a qualified financial or tax advisor before making any decisions regarding the disposition of the stock resulting from the vesting of these awards.   

These awards are in recognition of what you have done and continue to do for Pfizer, its patients, employees and shareholders.  I have great confidence in Pfizer’s future, and I look forward to working with you toward that future.  

Sincerely,
[SIGNATURE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]